Peppermint oil (Mentha x piperita) has transitioned from a traditional herbal remedy to a cornerstone of gastrointestinal (GI) medicine. As the "Best Peppermint Oil Capsule Suppliers & Service" provider, Jiangxi Serum Pharma Industries Co., Ltd. recognizes the shift toward high-purity, enteric-coated formulations. The global market is witnessing an unprecedented surge in demand for these capsules, primarily driven by the increasing prevalence of Irritable Bowel Syndrome (IBS) and the growing consumer preference for botanical-based therapeutics with clinical validation.
According to recent pharmaceutical market analysis, the global peppermint oil capsule market is projected to grow at a CAGR of 7.4% through 2030. Key trends include:
Professional supplier of pharmaceutical and nutritional products in China.
Established Year
Long-term Clients
Strategic Suppliers
Annual Sales (USD)
For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts. Our mission is to bridge the gap between high-quality Chinese manufacturing and global healthcare needs.
Utilizing high-speed, automated encapsulation lines that ensure zero-leakage and precise enteric coating thickness (within ±2 microns), crucial for ensuring the peppermint oil bypasses the stomach to reach the lower intestine.
Every batch of Mentha piperita is logged via blockchain from harvest to the finished capsule, ensuring 100% transparency in the global supply chain.
China's industrial ecosystem allows for rapid scaling. Our "Factory 4.0" approach reduces lead times by 30% compared to traditional Western manufacturing hubs without compromising GMP standards.
Monitoring the development of cutting-edge markets with specialized customization.
Customized formulation blends for optimized therapeutic effects.
Improving the stability and bioavailability of active pharmaceutical ingredients.
Sustainable production of high-purity nutritional ingredients.
Large-scale pharmaceutical buyers in the EU, North America, and Southeast Asia look for specific "Information Increments" when selecting a supplier. It's no longer just about the Certificate of Analysis (CoA). It’s about compliance adaptability.
Our service model addresses these localized needs by providing tailored documentation and formulation adjustments that respect regional regulatory nuances. This is the cornerstone of our "Suppliers & Service" promise.
Exploring the shift toward sustainable sources in the pharmaceutical industry.
Learn More
Why this molecule remains critical in modern medical treatments.
Learn MoreFDA approval of Lilly's oral GLP1 drug sets new records for the industry.
Learn More
